PTC Therapeutics Inc
NASDAQ:PTCT

Watchlist Manager
PTC Therapeutics Inc Logo
PTC Therapeutics Inc
NASDAQ:PTCT
Watchlist
Price: 46.3 USD 0.13%
Market Cap: 3.6B USD
Have any thoughts about
PTC Therapeutics Inc?
Write Note

PTC Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PTC Therapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
PTC Therapeutics Inc
NASDAQ:PTCT
Revenue
$900.7m
CAGR 3-Years
22%
CAGR 5-Years
25%
CAGR 10-Years
49%
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

PTC Therapeutics Inc
Revenue Breakdown

Breakdown by Geography
PTC Therapeutics Inc

Total Revenue: 937.8m USD
100%
United States: 531.7m USD
56.7%
Non-Us: 406.2m USD
43.3%

Breakdown by Segments
PTC Therapeutics Inc

Not Available

PTC Therapeutics Inc
Glance View

Market Cap
3.6B USD
Industry
Biotechnology

Nestled in the heart of the biotechnology sector, PTC Therapeutics Inc. has carved a distinctive niche by foregrounding innovative genetic approaches to combat rare diseases. Founded in 1998, the company harnesses the power of science and technology to address unmet medical needs, focusing primarily on disorders originating from genetic mutations that disrupt cellular systems. At its core, PTC leverages its expertise in the discovery and development of small molecule drugs and gene therapies, an endeavor propelled by its proprietary technology platforms such as SmRT (suppressor of nonsense mutations readthrough) and dystrophin restoration technologies. These platforms enable PTC to target and modify specific gene expressions, offering potential treatments for conditions such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), which have historically eluded effective therapies. The company’s revenue generation pivots on two key streams: product sales and strategic collaborations. By marketing its FDA-approved therapies like Translarna and Emflaza for rare genetic disorders, PTC secures a steady flow of income that underscores its sustainable business model. Additionally, PTC forms strategic alliances and collaborative agreements with pharmaceutical giants, fostering a vibrant environment of shared knowledge and resources. These partnerships not only bolster its research and development capabilities but also offer potential milestone payments and royalties, further strengthening its financial portfolio. In this symbiotic landscape, PTC Therapeutics continues to navigate the complexities of biotech development, striving to transform the challenges of rare diseases into treatment opportunities, thereby weaving innovation into the very fabric of business efficacy.

PTCT Intrinsic Value
24.83 USD
Overvaluation 46%
Intrinsic Value
Price

See Also

What is PTC Therapeutics Inc's Revenue?
Revenue
900.7m USD

Based on the financial report for Sep 30, 2024, PTC Therapeutics Inc's Revenue amounts to 900.7m USD.

What is PTC Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
49%

Over the last year, the Revenue growth was 13%. The average annual Revenue growth rates for PTC Therapeutics Inc have been 22% over the past three years , 25% over the past five years , and 49% over the past ten years .

Back to Top